Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14089988 | 0.83 | MC4R (0.58) | SIGMAR1ACHE | |
| SCHEMBL422176 | 0.75 | SIGMAR1 (0.76) | SLC6A3SIGMAR1ACHEHTR1ADRD2 | |
| SCHEMBL9851609 | 0.74 | CYP2D6 (0.58) | — | |
| SCHEMBL6897743 | 0.73 | SLC6A3 (0.68) | SLC6A3SIGMAR1ACHEHTR1ADRD2 | |
| SCHEMBL14407778 | 0.73 | SLC6A3 (0.83) | SLC6A3SIGMAR1ACHEHTR1ADRD2 | |
| SCHEMBL7264546 | 0.73 | SLC6A3 (0.83) | SLC6A3SIGMAR1ACHEHTR1ADRD2 | |
| SCHEMBL6056974 | 0.73 | SLC6A3 (0.83) | SLC6A3SIGMAR1ACHEHTR1ADRD2 | |
| SCHEMBL13150782 | 0.73 | SLC6A3 (0.83) | SLC6A3SIGMAR1ACHEHTR1ADRD2 | |
| SCHEMBL27671990 | 0.73 | SLC6A3 (0.52) | SLC6A3SIGMAR1HTR1ADRD2 | |
| SCHEMBL21650852 | 0.72 | SIGMAR1 (0.61) | SLC6A3SIGMAR1ACHEHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | SLC6A3 4823/4885SIGMAR1 4395/4885ACHE 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.